---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-093710"
form_type: "8-K"
ticker: "BTAI"
cik: "0001720893"
company_name: "BioXcel Therapeutics, Inc."
filed_at: "2026-08-11T11:00:24+00:00"
generated_at: "2026-08-11T11:05:38.507677+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# BioXcel extends debt repayment deadline to Aug 21, 2026; liquidity covenant cut to $3M

## Summary
- Twelfth Amendment to Credit Agreement with Oaktree dated Aug 10, 2026 extends acceptable transaction deadline from Aug 10 to Aug 21, 2026.
- Minimum liquidity covenant reduced to $3.0M from $6.25M effective Aug 10, 2026.
- Deadline requires definitive agreements for full repayment or alternative capital solution acceptable to Majority Lenders.
- Security Agreement amended to add three commercial tort claims as collateral (Cognitive Research, Caitlin Meyer, Segal Institute).
- All other Credit Agreement terms remain in full force; amendment does not waive lender rights.

## SEC filing metadata
- accession: 0001104659-26-093710
- form_type: 8-K
- ticker: BTAI
- cik: 0001720893
- company_name: BioXcel Therapeutics, Inc.
- filed_at: 2026-08-11T11:00:24+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1720893/000110465926093710/0001104659-26-093710-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1720893/000110465926093710/tm2622818d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-093710
- JSON: https://secwatch.observer/filing/0001104659-26-093710.json
- Plain text: https://secwatch.observer/filing/0001104659-26-093710.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.